Every year, alongside Nikki Zimmerman and the Rare Dementia Support (RDS) team, we organise a support group meeting for families living with familial frontotemporal dementia (fFTD). This is a fantasti...
What are fluid biomarkers and what are they used for? Fluid biomarkers typically refer to proteins in the blood or cerebrospinal fluid (CSF) that inform us of disease onset and progression. Importa...
Since our last new members introductory blog back in 2021 there’s been quite a lot of change to the team, so we wanted to introduce everyone again. We hope that this way you can get to know a bit ab...
The annual Alzheimer’s Association International Conference (AAIC) took place earlier this summer in Amsterdam, the Netherlands. The conference brings together experts from around the worl...
Every year, alongside the main GENFI summer meeting (see our previous blog post for a full rundown), we hold our annual Participant Engagement Board (PEB) meeting. This is a roundtable discussion betw...
Two new papers have been published by our team this month highlighting the role of inflammation in the brain in people with FTD. Both papers have been led by Aitana Sogorb Esteve from our team. The...
We have a new paper out this week led by Georgia Peakman investigating how we might measure the progression of symptoms in FTD. This uses data from the GENFI study to look at the only two commonly use...
Two recent papers from our team led by Martina Bocchetta have highlighted the importance of brain regions outside of the frontal and temporal lobes in FTD. Although FTD is named after these two lob...
We have a new paper out this week led by Hannah Franklin, who was a PhD rotation student with us last year. She focused on using a questionnaire called the Revised Self-Monitoring Scale (RSMS) that we...
Approximately one third of all people with FTD are genetic, and research has shown that changes in the brain associated with FTD can occur years before any symptoms (or presymptomatically). We need to...
